A clinical practice guideline on medicines optimisation is being developed by the National Institute for Health and Care Excellence for use in the NHS in England, Wales and Northern Ireland. The Royal Pharmaceutical Society (RPS) is registered as a stakeholder to comment on the provisional recommendations. Members are invited to submit their views to inform the RPS’s response (email Heidi.wright@rpharms.com).
Last updated